Natural history of noninfectious, ibrutinib-attributable adverse events in patients with chronic lymphocytic leukemia

Click to increase image sizeClick to decrease image size

Acknowledgements

The authors would like to acknowledge and thank the patients and their families treated at the Ohio State University and Oregon Health Sciences University. The research was presented in part at the American Society of Hematology 58^th annual meeting and exposition, San Diego, December 3-6, 2016.

Author contributions

SK, PS, CL, TW, SES, FTA collected and analyzed the data, wrote and edited the manuscript. XM analyzed the data, and wrote and edited the manuscript. SK, PS, CL, XM, TW, KR, LAA, JW, JCB, SES and FTA provided insight to study design, patient care, reviewed the data and wrote and edited the manuscript.

Disclosure statement

FTA has served as a consultant for Abbvie, AstraZeneca, Acerta Pharma, Celgene, Blueprint Medicine, Gilead, Genentech, Janssen, Sunesis, Dava Oncology, Kite Pharma, Karyopharm, Verastem, MEI Pharma, Incyte. JCB is a consultant for AstraZeneca, Genentech, Acerta, and Pharmacyclics. KAR received research funding from Genentech, AbbVie, and Janssen, has consulted for Acerta Pharma, and received travel funding from AstraZeneca. LAA has served as a consultant for AstraZeneca. JAW has consulted for Pharmacyclics and Janssen and receives research funding from Pharmacyclics, Janssen, Morphosys, Karyoparm, Loxo, Abbvie, and Verastem. SES has received research funding from Acerta Pharma, Gilead Sciences Inc., Janssen, Genentech, AstraZeneca, and Bristol Myers Squibb and has provided consulting services to Gilead Sciences, Janssen, Portola Pharmaceuticals and Pharmacyclics Inc.

Additional information

Funding

This work is supported by the OSU Leukemia Tissue Bank supported by NIH grant; P30 CA016058, National Cancer Institute (R35 CA198183), Four Winds Foundation and the D. Warren Brown Foundation. KAR is a Scholar in Clinical Research of the Leukemia & Lymphoma Society.